Treatment initiation cited in study comparing extended ‐release naltrexone, buprenorphine

A 24‐week open‐label trial has found that for patients with an opioid use disorder who could be successfully inducted to treatment, injectable extended‐release naltrexone (XR‐NTX) and buprenorphine‐naloxone (BUP‐NX) showed similar outcomes on measures of relapse and abstinence. The challenge of initiating patients on XR‐NTX, which requires that they be completely opioid‐free before starting on the medication, did result in poorer overall outcomes among the full cohort of patients randomized to XR‐NTX, however. Results were published online Nov. 14, 2017, in The Lancet.

Source: The Brown University Psychopharmacology Update - February 9, 2018 Category: Psychiatry Tags: Addiction Treatment Source Type: research